Caris Life Sciences (NASDAQ:CAI) Releases Earnings Results, Beats Estimates By $0.02 EPS

Caris Life Sciences (NASDAQ:CAI) issued its earnings results on Wednesday. The company reported $0.05 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.02, FiscalAI reports. Caris Life Sciences had a net margin of 10.62% and a return on equity of 18.77%. The company had revenue of $275.36 million during the quarter. During the same period in the prior year, the company posted $0.08 EPS. The company’s quarterly revenue was up 27.0% on a year-over-year basis.

Here are the key takeaways from Caris Life Sciences’ conference call:

• Growth accelerated: Third-quarter revenue rose 27% year over year to $275.4 million, while clinical case volume increased 21% to approximately 61,500. Management attributed the momentum to sales-force expansion and said it expects volume to reach about 65,000 cases in Q4.
• Full-year revenue outlook increased to approximately $1.04 billion–$1.05 billion, from $1.03 billion–$1.04 billion. Caris also reported $15.3 million in quarterly GAAP net income and its sixth consecutive quarter of positive adjusted EBITDA.
• Caris is extending its product portfolio across cancer detection, treatment monitoring, and post-treatment surveillance, with Caris Assure Therapy Response Monitoring launched and Caris Confirm planned for December. Reimbursement work is still underway for the new products, and the next interim readout from the 25,000-participant ACHIEVE-2 study is expected in Q1 2027.
• Investment and cash use remain key watch points: Operating expenses rose $48.1 million year over year, and quarterly free cash flow was negative $39.7 million, partly due to planned inventory and growth investments. Management expects positive free cash flow for Q4 and the full year, but raised its operating-expense outlook to approximately $620 million.

Caris Life Sciences Price Performance

NASDAQ CAI traded down $7.00 on Thursday, reaching $26.22. The company had a trading volume of 1,751,932 shares, compared to its average volume of 3,398,917. The stock has a market capitalization of $7.41 billion, a PE ratio of 73.63 and a beta of 0.71. Caris Life Sciences has a 12 month low of $14.19 and a 12 month high of $36.50. The company has a quick ratio of 4.88, a current ratio of 5.53 and a debt-to-equity ratio of 0.66. The firm’s 50 day moving average price is $29.52 and its 200 day moving average price is $21.74.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on CAI shares. UBS Group set a $38.00 price objective on Caris Life Sciences in a research report on Thursday. Wall Street Zen upgraded Caris Life Sciences from a “sell” rating to a “hold” rating in a research report on Sunday, August 16th. Evercore reissued an “outperform” rating and set a $26.00 target price on shares of Caris Life Sciences in a research note on Thursday, August 6th. Weiss Ratings cut Caris Life Sciences from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, October 2nd. Finally, Canaccord Genuity Group upped their price target on Caris Life Sciences from $22.00 to $30.00 and gave the stock a “hold” rating in a research note on Monday, October 19th. Eight research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Caris Life Sciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.91.

Insider Buying and Selling at Caris Life Sciences

In related news, President David Spetzler sold 478,000 shares of the business’s stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $24.86, for a total value of $11,883,080.00. Following the sale, the president directly owned 1,052,083 shares in the company, valued at approximately $26,154,783.38. The trade was a 31.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider John Russel Denton sold 7,500 shares of the business’s stock in a transaction dated Tuesday, September 22nd. The stock was sold at an average price of $31.82, for a total value of $238,650.00. Following the completion of the sale, the insider owned 174,855 shares in the company, valued at $5,563,886.10. This represents a 4.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 1,004,712 shares of company stock valued at $27,205,419 in the last 90 days. Insiders own 50.00% of the company’s stock.

Hedge Funds Weigh In On Caris Life Sciences

Several institutional investors have recently added to or reduced their stakes in CAI. Braidwell LP lifted its position in Caris Life Sciences by 3.1% in the second quarter. Braidwell LP now owns 8,256,032 shares of the company’s stock worth $147,122,000 after buying an additional 246,585 shares during the last quarter. PointState Capital LP bought a new position in Caris Life Sciences in the 2nd quarter valued at $121,690,000. BlackRock Inc. purchased a new stake in Caris Life Sciences in the second quarter worth $98,666,000. Canada Pension Plan Investment Board purchased a new stake in Caris Life Sciences in the second quarter worth $24,502,000. Finally, Amundi lifted its position in shares of Caris Life Sciences by 5,709.5% during the second quarter. Amundi now owns 1,218,364 shares of the company’s stock worth $21,711,000 after purchasing an additional 1,197,392 shares during the last quarter.

Key Caris Life Sciences News

Here are the key news stories impacting Caris Life Sciences this week:

• Positive Sentiment: Caris raised its 2026 revenue guidance to $1.04 billion–$1.05 billion, implying 28%–29% growth. Third-quarter revenue rose 27% year over year to $275.4 million, supported by molecular profiling services. Caris Q3 results and increased guidance
• Positive Sentiment: Adjusted earnings of $0.05 per share topped the $0.03 consensus estimate. BTIG Research also reaffirmed its Buy rating and $38 price target, above the cited $33.22 share price. Q3 earnings and revenue beat estimates
• Neutral Sentiment: A valuation article characterized CAI as trading about 14% below estimated fair value, though that assessment depends on the analysis’s assumptions. Caris valuation analysis
• Negative Sentiment: Despite revenue growth and the EPS beat, net income fell 37% as expenses increased. EPS was also below the $0.08 reported in the year-earlier quarter, tempering the otherwise positive results. Q3 net income decline and outlook

About Caris Life Sciences

Caris Life Sciences is a biotechnology and precision-medicine company that uses molecular profiling and artificial intelligence to support cancer diagnosis, treatment selection and drug development. The company analyzes tumor and blood samples to identify genomic, molecular and immune characteristics that may help physicians better understand a patient’s disease and select targeted therapies.

Its offerings include comprehensive tumor profiling, liquid-biopsy testing and data-driven clinical decision-support tools.